COVID-19-induced alopecia: a clinical case of diffuse focal alopecia in a patient with generalized pustular psoriasis after a new coronavirus infection

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The clinical picture of dermatological diseases in synergy with the pandemic of coronavirus infection demonstrates various, additional, more striking features of the course of dermatoses. The proposed case of observation illustrates the development of diffuse alopecia in a patient with torpid generalized pustular psoriasis, metabolic syndrome, endocrinopathy against the background of a coronavirus infection complicated by polysegmental pneumonia.

In the presented clinical observation, the severity of the lesion of the skin and skin appendages correlated with the severity of the course of COVID-19, which was the trigger point of the general pathological process ― immune-mediated T-cell inflammation. In the manifestation of psoriasis and its exacerbation, a significant role was played by viral load and a pronounced comorbid background ― autoimmune thyroid disease and metabolic syndrome. Thus, the severe course of COVID-19 with involvement in the pathological process of the microcirculatory bed, coagulopathy, hypoxia of hair follicles as a result, as well as the reduced estrogenic background of the sixty-one-year-old patient contributed not only to the exacerbation of psoriasis, but also led to diffuse hair loss. The degree of hair loss according to SALT criteria was 82%, which corresponded to a severe degree of lesion. The use of prolonged-acting injectable corticosteroids in the complex treatment of various forms of alopecia was an effective method of therapy in this patient, which is associated with the immunosuppressive effect of corticosteroids in autoimmune damage to hair follicles, a decrease in inflammation of the microvascular bed in various infectious and inflammatory conditions. In the presented case, the high efficiency may also have been associated with the mechanisms of reducing the damaging effect of cytokine inflammatory factors, expressed both with the existing background disease psoriasis and with coronavirus complicated infection.

As numerous observations show, COVID-19 is a potential trigger for many dermatological conditions. Examination and treatment of patients with skin pathology infected with COVID-19 requires a systematic integrated approach.

Full Text

Restricted Access

About the authors

Marina S. Petrova

Moscow Regional Research and Clinical Institute

Author for correspondence.
Email: marina.s.petrova@gmail.com
ORCID iD: 0000-0002-1789-2311

MD, Research Associate

Russian Federation, 61/2, Shepkina street, Moscow, 129110

Maria G. Kartashova

Moscow Regional Research and Clinical Institute

Email: maxa.ka@mail.ru

MD, Cand. Sci. (Med.), Research Associate

Russian Federation, 61/2, Shepkina street, Moscow, 129110

Yulia V. Molochkova

Moscow Regional Research and Clinical Institute

Email: 79265542544@yandex.ru
ORCID iD: 0000-0003-0934-8903

MD, Dr. Sci. (Med.), Assistant Professor

Russian Federation, 61/2, Shepkina street, Moscow, 129110

Anton V. Molochkov

Moscow Regional Research and Clinical Institute

Email: anton.molochkov@gmail.com
ORCID iD: 0000-0002-6456-998X

MD, Dr. Sci. (Med.), Professor

Russian Federation, 61/2, Shepkina street, Moscow, 129110

Alexandr D. Varfolomeev

Moscow Regional Research and Clinical Institute

Email: doctor.varfolomeev@gmail.com
ORCID iD: 0000-0003-3807-9706

MD

Russian Federation, 61/2, Shepkina street, Moscow, 129110

References

  1. Guarner J. Three emerging coronaviruses in two decades. Am J Clin Pathol. 2020;153(4):420–421. doi: 10.1093/ajcp/aqaa029
  2. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8
  3. Temporary methodological recommendations “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) Version 10” (08.02.2021). Moscow; 2021. 262 p. (In Russ).
  4. Dvornikov AS, Silin AA, Gaidina TA, et al. Skin manifestations in coronavirus disease 2019 (COVID-19). Archive Int Med. 2020;10(6): 422–429. (In Russ). doi: 10.20514/2226-6704-2020-10-6-422-429
  5. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi: 10.1016/j. jaut.2020.102433
  6. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi: 10.1016/S2213-2600(20)30076-X
  7. Ramos MP, Ianhez M, Amante Miot H. Alopecia and grey hair are associated with COVID-19 Severity. Exp Dermatol. 2020;29(12): 1250–1252. doi: 10.1111/exd.14220
  8. Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. British J Dermatol. 2012;166(5):916–926. doi: 10.1111/j.1365-2133.2012.10955.x
  9. Samtsov AV, Sokolovsky EV. Rational pharmacotherapy of skin diseases and sexually transmitted infections. Moscow: LitTerra; 2021. Р. 522–523. (In Russ).
  10. Spano F, Donovan JC. Alopecia areata. Part 1: pathogenesis, diagnosis, and prognosis. Can Fam Physician. 2015;61(9):751–755.
  11. Arenas MÁ, Del Carpio-Toia A, Galdos AJ, Rodriguez-Morales AJ. Alopecia and severity of COVID-19: a cross-sectional study in Peru. Infez Med. 2021;29(1):37–45.
  12. Olsen EA, Canfield D. SALT II: a new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol. 2016;75(6):1268–1270. doi: 10.1016/j.jaad.2016.08.042
  13. Adaskevich VP. Diagnostic indices in dermatology. Moscow: BINOM; 2014. 56 p. (In Russ).
  14. Rybakova MG, Karev VE, Kuznetsova IA. Pathological anatomy of a new coronavirus infection COVID-19. First impressions. Archive Pathology. 2020;82(5):5–15. (In Russ). doi: 10.17116/patol2020820515
  15. Melo DF, Dutra TB, Baggieri VM, Tortelly VD. Intralisional betamethasone as a therapeutic option for the treatment of focal alopecia. An Bras Dermatol. 2018;93(2):311–312. doi: 10.1590/abd1806-4841.20187423

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Patient A., 61 years old. Diffuse alopecia after a COVID-19 infection.

Download (1MB)
3. Fig. 2. Diagram of hair growth zones for SALT assessment [12].

Download (192KB)
4. Fig. 3. Uniform hair growth in all areas 6 months after the therapy.

Download (365KB)

Copyright (c) 2022 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г
.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies